Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
1.
J Thyroid Res ; 2012: 168764, 2012.
Article in English | MEDLINE | ID: mdl-23251828

ABSTRACT

Aim. To assess the impact of iodine status in early pregnancy on thyroid function. Methods. Women >18 years old seen at their first prenatal consult before 12 weeks of amenorrhea and without personal thyroid history were proposed thyroid screening and were eligible if they had strictly normal thyroid tests (fT4 > 10th percentile, TSH < 2.5 mUI/L, negative anti-TPO antibodies). Evaluation included thyroid ultrasound, extensive thyroid tests, and ioduria (UIE). Results. 110 women (27.5 y, 8 weeks of amenorrhea, smoking status: 28% current smokers) were enrolled. Results are expressed as medians. UIE was 116 µg/L. 66.3% of women had iodine deficiency (ID) defined as UIE < 150. FT4 was 14.35 pmol/L; TSH 1.18 mUI/L; fT3 5 pmol/L; thyroglobulin 17.4 ng/mL; rT3 0.27 ng/mL; thyroid volume: 9.4 ml. UIE did not correlate with any thyroid tests, but correlated negatively with thyroid volume. UIE and all thyroid tests, except fT3, correlated strongly with ßhCG. Smoking correlated with higher thyroid volume and thyroglobulin and with lower rT3. Conclusions. In pregnant women selected for normal thyroid function, mild ID is present in 66% during the 1st trimester. The absence of correlation between UIE and thyroid tests at that stage contrasts with the impact of ßhCG and, to a lesser degree, maternal smoking.

2.
Hum Reprod ; 27(4): 983-90, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22267833

ABSTRACT

BACKGROUND: Human toxicity of bisphenol A (BPA), a weak estrogenic environmental endocrine disrupting compound, widely used in plastics, baby bottles, cans and dental sealants, is under investigation. Fetal or perinatal exposure in rodents is associated with programmed adult reproductive diseases. Human epidemiological studies remain scarce, especially concerning testicular development. We have investigated the relationship between fetal exposure to BPA and cryptorchidism. METHODS: Using a radioimmunoassay performed after extraction, validated by high-performance liquid chromatography and mass spectrometry, active levels of unconjugated BPA (uBPA) in cord blood (CB) were measured in 152 boys born after 34 weeks gestation, with cryptorchid or descended testes. RESULTS: Active uBPA was detectable in all CB samples, with values in the control group (n = 106) of 0.14-4.76 ng/ml, median: 0.9 ng/ml; mean ± SD: 1.12 ng/ml ± 0.86 ng/ml, which did not differ from cryptorchid boys (n = 46, 1.26 ± 1.13 ng/ml, P = 0.38). uBPA in controls correlated with CB inhibin B (P < 0.01) and total testosterone (P < 0.05), and with maternal milk polychlorinated bisphenyl 138 (P < 0.03). uBPA did not correlate with clinical maternal or fetal parameters or with other steroid or polypeptide CB hormones assessed. CONCLUSIONS: The presence of uBPA in all CB samples suggests placental transfer and fetal exposure. Similar uBPA levels in the control and cryptorchid groups make the participation of fetal exposure to uBPA in the physiopathology of undescended testes unlikely. However, the observed nanomolar uBPA concentrations support assessment of epidemiological relationships between CB uBPA and other human diseases.


Subject(s)
Boron Compounds/blood , Cryptorchidism/blood , Endocrine Disruptors/blood , Environmental Exposure/analysis , Fetal Blood/metabolism , Phenylalanine/analogs & derivatives , Boron Compounds/toxicity , Chromatography, High Pressure Liquid , Endocrine Disruptors/toxicity , Female , Humans , Infant, Newborn , Male , Mass Spectrometry , Milk, Human/chemistry , Phenylalanine/blood , Phenylalanine/toxicity , Pregnancy , Prenatal Exposure Delayed Effects , Testosterone/blood
3.
Int J Androl ; 34(5 Pt 2): e499-510, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21831232

ABSTRACT

To assess the incidence and risk factors of cryptorchidism in Nice area. A 3-year prospective study was conducted at two maternity wards involving neonatal screening of boys born ≥34weeks of amenorrhoea. Methodology was strict with examination at birth, 3 and 12months by the same paediatrician. Two strictly matched controls were included for each case. Information on child and parents (medical history, pregnancy, lifestyle) was recorded using medical chart and self-administered questionnaires. A total of 102 of 6246 boys were born with cryptorchidism (prevalence 1.6%, 95 included). Half of them were still cryptorchid at three and 12months with, however, 10% of secondary re-ascent (recurrent cryptorchidism) at 12months, justifying long-term follow-up. Cryptorchidism at birth was associated with instrumental delivery, inguinal hernia and urogenital malformations, particularly micropenis and paternal history of cryptorchidism. Our results suggest that maternal exposure to anti-rust or phthalates could be a risk factor, whereas eating fruits daily seemed somewhat protective. Prevalence of cryptorchidism in our area is on the lower bracket compared with other countries, and is associated with both familial and environmental risk factors.


Subject(s)
Cryptorchidism/epidemiology , Case-Control Studies , Cryptorchidism/etiology , Female , France/epidemiology , Humans , Infant , Infant, Newborn , Male , Maternal Exposure/adverse effects , Pregnancy , Prevalence , Prospective Studies , Risk Factors
4.
Diabetes Metab ; 37(5): 419-25, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21489844

ABSTRACT

AIM: Currently, there is no international consensus for gestational diabetes mellitus (GDM) diagnosis. This is a report of our experience of GDM screening according to the 1996 French guidelines. METHODS: For 5 years, all pregnant women followed at our hospital (n=11,545) were prospectively screened for GDM between weeks 24 and 28 of pregnancy with a two-step strategy: the O'Sullivan test (OS) with a threshold at 130 mg/dL, followed by a 100-g OGTT if positive. GDM was diagnosed according to Carpenter and Coustan criteria. RESULTS: Prevalence of GDM was 4.26% [344/1451 of patients with an OS of 130-199 mg/dL (12.1%); and 148 patients with an OS greater than 200 mg/dL]. The false-positive rate for the OS was 76.8%. Compared with 140 mg/dL, a threshold of 130 mg/dL caused 401 additional negative OGTTs in 90% of cases. In 80.7% GDM patients, fasting glucose was less than 95 mg/dL. The time lag between OS and OGTT was 3 weeks (1-84 days). Risk factors associated with GDM were maternal age, preconception overweight and obesity, parity, personal history of GDM or macrosomia, and familial history of obesity (P<0.05), but not diabetes. Also, 20% of GDM patients had no risk factors, whereas they were present in 75% of patients without GDM. CONCLUSION: In our population, a two-step screening strategy for GDM was neither relevant nor efficient. It could be simplified with a single-step definitive screening strategy using a 75-g OGTT, as used in the HAPO study, and as recommended by the IADPSG and the recent French Expert Consensus. At present, there are still no evidence-based arguments to help in deciding between selective or universal screening for GDM.


Subject(s)
Diabetes, Gestational/diagnosis , Diabetes, Gestational/epidemiology , Mass Screening/methods , Mass Screening/statistics & numerical data , Adult , Body Mass Index , Female , France/epidemiology , Glucose Intolerance/diagnosis , Glucose Intolerance/epidemiology , Glucose Tolerance Test/methods , Glucose Tolerance Test/statistics & numerical data , Humans , Mediterranean Region/epidemiology , Obesity/diagnosis , Obesity/epidemiology , Pregnancy , Prevalence , Prospective Studies , Risk Factors , Sensitivity and Specificity
5.
Ann Endocrinol (Paris) ; 71(6): 535-42, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20934171

ABSTRACT

GOALS: To report cases of embryopathy occurring following first trimester exposure to anti-thyroid drugs. METHODS: Retrospective screening of the database of our Pharmacovigilance Center from 1987 to date. RESULTS: We report six cases of embryopathy, all following carbimazole exposure during the first trimester: two cases of abdominal wall defect, including one associated with facial dysmorphia; one case of digestive malformation (patent omphalomesenteric duct); two cases of aplasia cutis including one with facial dysmorphism; one case of bilateral choanal atresia with aorta coarctation associated with poorly controlled insulin dependent diabetes. Four out of five patients were euthyroid with treatment during the first trimester. We found a context suggesting genetic predisposition to congenital malformation in three cases: two cases of parental cleft lip/palate, one case of consanguinity. Outcome was favorable in all cases. CONCLUSIONS: We want to raise awareness about the potential teratogenicity of carbimazole, probably on a predisposed genetic background. We suggest better reporting of congenital anomalies in children of women with Graves'disease, with or without in utero exposure to anti-thyroid drugs. In light of current literature, propylthiouracil should be the first line treatment for hyperthyroid women wishing a pregnancy.


Subject(s)
Abnormalities, Drug-Induced/epidemiology , Antithyroid Agents/adverse effects , Carbimazole/adverse effects , Abdominal Wall/abnormalities , Adult , Antithyroid Agents/therapeutic use , Carbimazole/therapeutic use , Consanguinity , Databases, Factual , Digestive System Abnormalities/chemically induced , Ectodermal Dysplasia/chemically induced , Female , Fetal Diseases/chemically induced , France/epidemiology , Graves Disease/complications , Graves Disease/drug therapy , Hernia, Umbilical/chemically induced , Humans , Male , Pregnancy , Pregnancy Complications/drug therapy , Product Surveillance, Postmarketing , Prospective Studies
6.
Ann Endocrinol (Paris) ; 71(6): 548-52, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20850107

ABSTRACT

Cushing's disease is usually associated with higher mortality rate, especially from cardiovascular causes. Development or exacerbation of autoimmune or inflammatory diseases is known to occur in patients with hypercortisolism after cure. We report for the first time a 34-year old woman with a psychiatric background, who developed four months after the surgical cure of Cushing's disease an acute disseminated encephalomyelitis (ADEM) presenting initially as a psychiatric illness. We hypothesize that the recent correction of hypercortisolism triggered ADEM and that the atypical presentation, responsible for diagnosis delay, led to the death of this patient.


Subject(s)
Demyelinating Diseases/etiology , Encephalomyelitis/etiology , Pituitary ACTH Hypersecretion/complications , Adrenocorticotropic Hormone/blood , Adult , Blood Glucose/metabolism , Brain/pathology , Demyelinating Diseases/pathology , Encephalomyelitis/pathology , Fatal Outcome , Female , Humans , Hydrocortisone/blood , Immunohistochemistry , Magnetic Resonance Imaging , Obesity/complications , Pituitary ACTH Hypersecretion/pathology , Pituitary ACTH Hypersecretion/surgery , Psychotic Disorders/complications , Suicide, Attempted
8.
Ann Endocrinol (Paris) ; 70(4): 218-24, 2009 Sep.
Article in French | MEDLINE | ID: mdl-19481731

ABSTRACT

BACKGROUND: Iodine deficiency (ID) is still common in Western Europe and its prevention remains a challenge, particularly during pregnancy. METHODS: We studied 330 pregnant women in the third trimester of pregnancy for ioduria (UIE) and thyroid tests (TSH, fT4). We collected information on personal history of thyroid disease and treatment with thyroid hormones or iodinated pregnancy tablets. RESULTS AND DISCUSSION: Median UIE was 64 microg/l, reflecting inadequate iodine intake in our population. According to the UIE threshold used for diagnosis (100 to 150 microg/l), ID was present in 74.3% to 85.8% of women; 5.4% had excessive iodine intake, including one taking iodine fortified tablets. Only 8.8% had adequate intake, suggesting that current strategies to eradicate ID are inefficient in our country. Among the 22 women taking iodine supplements, only three had adequate UIE and four had UIE below the detection level, which could suggest either poor compliance or insufficient supplementation. Median fT4 was 12.3pmol/l (8-20.1) and TSH 1.93mUI/l (0.24-6.57). We used different thresholds proposed in the literature to diagnose: hypothyroxinemia: 41.2% were less than 12pmol/l, 10% less than 10.3pmol/l and 1.8% less than 9pmol/l (lower limit of our reference range); subclinical hypothyroidism: 26.3% had TSH greater than 2.5 or 3.9% greater than 4mUI/L, 1.2 to 13% had combined low fT4 (<9pmol/l or <12pmol/) and higher TSH (>2.5mUI/l). There was no correlation between UIE and thyroid tests, nor maternal predicting factors for ID. CONCLUSION: ID is common in our population. The wide range of hypothyroxinemia and subclinical hypothyroidism prevalence should also trigger reflection of diagnostic thresholds and therapeutic intervention.


Subject(s)
Iodine/deficiency , Pregnancy Trimester, Second/physiology , Pregnancy Trimester, Third/physiology , Thyroid Gland/physiology , Adult , Female , Humans , Hypothyroidism/epidemiology , Iodine/blood , Iodine/urine , Pregnancy , Pregnancy Complications/epidemiology , Pregnancy Complications/physiopathology , Thyroid Function Tests , Thyrotropin/blood , Thyroxine/blood
9.
Gynecol Obstet Fertil ; 36(10): 969-77, 2008 Oct.
Article in French | MEDLINE | ID: mdl-18805035

ABSTRACT

Human epidemiological studies and experimental animal data strongly suggest that xenobiotics with estrogenic activity may participate in to the increasing incidence of breast cancer, the most frequent cancer all around the world. Several reports have since 15 years reported positive correlations between blood or peritumoral adipose tissue levels of persistent organic compounds including organochloride pesticides and breast cancer risk. Moreover, fetal or perinatal exposition to low doses of such endocrine disruptors induce premalignant or malignant transformation of adult mammary gland in rodents. However, this environmental endocrine disrupter hypothesis still needs to be demonstrated. Further human studies are needed which will consider the exposition window, the association of several xenoestrogens, the molecular mechanisms involved and the possible individual genetic susceptibility in order to identify pertinent biomarkers and to define acceptable environmental concentration levels for agricultural or industrial chemical new products to be used.


Subject(s)
Breast Neoplasms/chemically induced , Breast Neoplasms/epidemiology , Breast/drug effects , Carcinogens, Environmental/toxicity , Endocrine Disruptors/toxicity , Breast/metabolism , Environmental Exposure , Female , Humans , Pesticide Residues/toxicity , Risk Factors
10.
Gynecol Obstet Fertil ; 36(9): 840-7, 2008 Sep.
Article in French | MEDLINE | ID: mdl-18707911

ABSTRACT

OBJECTIVE: Numerous maternal lipophilic compounds are eliminated into milk during lactation, their concentrations reflecting fetal in utero exposure. Some of them are endocrine disruptors. Their role in the occurrence of genital malformation, dysfunction or cancer has been suggested. We wanted to study the exposure of our population and its potential association with cryptorchidism, as few clinical studies are available. PATIENTS AND METHODS: Over three years, we screened for cryptorchidism all boys born alive at or above 34 weeks of gestational age, in two maternity wards (CHU Nice, CHG Grasse). Cryptorchid boys were matched with two controls. Nursing mothers provided a colostrum sample that was screened for 15 compounds known for their antiandrogenic and/or anti estrogenic properties, including dichloro-diphenyl-trichloro-ethylene (DDE), polychlorinated biphenyls (PCBs), dibutylphthalate (DBP) (& metabolite monobutylphthalate-mBP) and hexachlorobenzene (HCB). RESULTS: Out of 6246 boys, 102 were cryptorchid (1.6%). All available colostrums (56 for cryptorchid and 69 for controls) were contaminated. Median concentrations of DDE, PCBs, HCB and phthalates were higher though not significantly in cryptorchid versus controls. Cryptorchid boys were more likely to be classified in the most contaminated groups for DDE and SigmaPCBs, with a trend for mBP. Odds ratio (OR) for cryptorchidism was increased for the highest score of SigmaPCB, with a trend only for DDE versus the lowest score of those components. Our results are similar to those of a Scandinavian study with comparable design. DISCUSSION AND CONCLUSIONS: Our results show the universal contamination of milk with endocrine disruptors in our area, and support the association between congenital cryptorchidism and fetal exposure to PCBs and possibly DDE, alone or in association with other chemicals.


Subject(s)
Colostrum/chemistry , Cryptorchidism/chemically induced , Maternal Exposure/adverse effects , Milk, Human/chemistry , Pesticides/toxicity , Adult , Case-Control Studies , Cryptorchidism/epidemiology , Dichlorodiphenyl Dichloroethylene/analysis , Dichlorodiphenyl Dichloroethylene/toxicity , Environmental Pollution , Female , Humans , Infant, Newborn , Male , Pesticides/analysis , Polychlorinated Biphenyls/analysis , Polychlorinated Biphenyls/toxicity
11.
Ann Endocrinol (Paris) ; 69(5): 453-8, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18620332

ABSTRACT

Testicular adrenal rest tumours are frequently associated with congenital adrenal hyperplasia (CAH). These ACTH-dependent tumours cannot be easily distinguished histologically from Leydig-cell tumours. We report the case of a 30-year-old man who was explored for infertility, azoospermia and unilateral testicular tumour. High levels of 17-OH progesterone and ACTH, low cortisol and undetectable gonadotropins levels, associated to bilateral adrenal hyperplasia, led to the diagnosis of CAH by 21-OH deficiency with a composite heterozygoty. The testicular tumour was first considered as adrenal rest. However, histological analysis of this unilateral painful tumour showed a steroid-hormone-secreting cell proliferation with atypical and frequent mitosis. To discriminate between a benign adrenal rest tumour and a possible malignant leydigioma, tumoral expression of specific gene products was analyzed by RT-PCR. No 11-beta-hydroxylase nor ACTH receptor mRNAs could be found in the tumour, which did not behave like usual adrenal rest cells. For this unilateral testicular tumour, the lack of adrenal-specific markers associated with a high rate of mitosis and pleiomorphism supported a leydigian origin with malignant potential. However, lack of tumoral LH-R mRNA expression and a tumour-free 3-year follow-up led us to retain the diagnosis of adrenal rest tumour with loss of adrenal gene expression and progressive autonomous behaviour.


Subject(s)
Adrenal Hyperplasia, Congenital/complications , Adrenal Hyperplasia, Congenital/diagnosis , Adrenal Rest Tumor/diagnosis , Leydig Cell Tumor/diagnosis , Testicular Neoplasms/complications , Testicular Neoplasms/diagnosis , Adrenal Cortex Hormones/blood , Adrenal Cortex Hormones/genetics , Adrenal Hyperplasia, Congenital/surgery , Adrenal Rest Tumor/pathology , Adrenal Rest Tumor/surgery , Adult , Anti-Inflammatory Agents/therapeutic use , Azoospermia/etiology , Biomarkers, Tumor , Dexamethasone/therapeutic use , Diagnosis, Differential , Gonadal Steroid Hormones/blood , Gonadal Steroid Hormones/genetics , Gonadotropins/blood , Humans , Infertility, Male/etiology , Leydig Cell Tumor/pathology , Leydig Cell Tumor/surgery , Male , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction , Testicular Neoplasms/surgery , Testis/pathology
12.
Ann Endocrinol (Paris) ; 68(1): 51-4, 2007 Feb.
Article in French | MEDLINE | ID: mdl-17313936

ABSTRACT

Struma ovarii is an ovarian teratoma mainly composed of thyroid tissue, which can become malignant with possible peritoneal dissemination or even distant metastases. Therapeutic management follows protocols used for thyroid cancer. We report the first use of (18)F-fluorodeoxyglucose positron emission tomography (PET) in the follow-up of malignant struma ovarii with persistently elevated serum thyroglobulin level and negative diagnostic iodine 131 whole body scan after thyroidectomy and four courses of 131 iodine. Hilar and mediastinal lymph node uptake was detected but histological verification concluded that there was a false-positive localization corresponding to sarcoidosis lesions without malignant aspect.


Subject(s)
Ovarian Neoplasms/diagnostic imaging , Positron-Emission Tomography , Sarcoidosis/diagnostic imaging , Adult , False Positive Reactions , Female , Fluorodeoxyglucose F18 , Humans , Radiopharmaceuticals , Thyroid Gland/pathology
13.
J Endocrinol Invest ; 26(6): 575-87, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12952375

ABSTRACT

Cryptorchidism is the most frequent developmental abnormality in boys, present in more than 1% of infants above three months of age. It is associated with an increased risk of infertility and testicular cancer. The etiological quest is often disappointing, except in bilateral cases or associated malformations. Recent focus is on genetic and environmental aspects. Animal models have revealed the role of genes encoding for proteins implicated in testicular migration (InsI3, Hoxa 10), but in humans results are less convincing. While some degree of endogenous hormonal abnormality is suspeeted in some patients, the endocrine disruptor hypothesis is also tested. It is unclear whether the incidence of cryptorchidism has really increased, or whether there is only a better screening for this condition. However, other male reproductive problems, such as subfertility, hypospadias and testicular cancer seem on the rise. This secular trend suggests the possible in utero impact of hormonally active environmental factors, such as pesticides with estrogenic or antiandrogenic effect, and is consistent with the increased risk of cryptorchidism observed in the sons of mothers exposed to diethylstilbestrol during pregnancy. From a therapeutic point of view, there is an agreement that the correction of cryptorchidism is needed, but there is controversy on the best medical and/or surgical approach and on the optimal timing. There is a recent trend in proposing early therapeutic intervention, before 1 yr of age, in the hope of improving fertility; however, there is no proof that such a strategy can reduce the risk of testicular cancer.


Subject(s)
Cryptorchidism/diagnosis , Cryptorchidism/therapy , Endocrine System/physiopathology , Environment , Cryptorchidism/etiology , Cryptorchidism/physiopathology , Hormones/blood , Humans , Incidence , Male , Prognosis , Risk Factors
14.
J Clin Endocrinol Metab ; 86(11): 5142-7, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11701667

ABSTRACT

Resistance to thyroid hormone (RTH) is a syndrome in which patients have elevated thyroid hormone (TH) levels and decreased sensitivity to its action. We describe a child with extreme RTH and a severe phenotype. A 22-month-old female presented to the NIH with goiter, growth retardation, short stature, and deafness. Additionally, the patient had hypotonia, mental retardation, visual impairment, and a history of seizures. Brain magnetic resonance imaging showed evidence of demyelination and bilateral ventricular enlargement. The patient had markedly elevated free T3 and free T4 levels of more than 2000 pg/dl (normal, 230-420 pg/dl) and more than 64 pmol/liter (normal, 10.3-20.6 pmol/liter), respectively, and TSH of 6.88 mU/liter (normal, 0.6-6.3 mU/liter). These are the highest TH levels reported for a heterozygous RTH patient. A T3 stimulation test confirmed the diagnosis of RTH in the pituitary and peripheral tissues. Molecular analyses of the patient's genomic DNA by PCR identified a single base deletion in exon 10 of her TRbeta gene that resulted in a frameshift and early stop codon. This, in turn, encoded a truncated receptor that lacked the last 20 amino acids. Cotransfection studies showed that the mutant TR was transcriptionally inactive even in the presence of 10(-6) M T3 and had strong dominant negative activity over the wild-type receptor. It is likely that the severely defective TRbeta mutant contributed to the extreme RTH phenotype and resistance in our patient.


Subject(s)
Thyroid Hormone Resistance Syndrome/genetics , Bone Development/physiology , Brain/pathology , Cells, Cultured , Female , Frameshift Mutation , Gene Deletion , Humans , Infant , Magnetic Resonance Imaging , Phenotype , Thyroxine/blood , Transcription, Genetic/genetics , Transfection , Triiodothyronine/blood
15.
Carcinogenesis ; 22(9): 1537-42, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11532877

ABSTRACT

Lindane (gamma-hexachlorocyclohexane) is a lipid-soluble pesticide that exerts carcinogenic and reprotoxic properties. The mechanisms by which lindane alters testicular function are unclear. Sertoli cells control germ cell proliferation and differentiation through cell-cell communication, including gap junction intercellular communication. Using the 42GPA9 Sertoli cell line, we show that lindane, at a non-cytotoxic dose (50 microM), abolished gap junction intercellular communication (GJIC) between adjacent cells. This change was associated with a time-related diminution and redistribution of Cx43 from the membrane to the cytoplasmic perinuclear region. A similar alteration was observed for ZO-1, a tight junction component associated with Cx43, but not for occludin, an integral tight junction protein. After a 24 h lindane exposure, Cx43 and ZO-1 colocalized within the cytoplasm and no modification of non-phosphorylated and phosphorylated isoforms of Cx43 was observed. By double immunofluorescent labelling we demonstrate that the cytoplasmic Cx43 signal was not present in either the endoplasmic reticulum/Golgi apparatus or lysosomes. These results suggest that lindane inhibits GJIC between Sertoli cells and that aberrant Cx43/ZO-1 localization may be responsible for this effect. The alterations in gap junctions induced by lindane in 42GPA9 Sertoli cells are similar to those observed in tumour cells and may be involved in the pathogenesis of neoplastic seminomal proliferation.


Subject(s)
Cell Communication/drug effects , Connexin 43/metabolism , Gap Junctions/drug effects , Hexachlorocyclohexane/toxicity , Membrane Proteins/metabolism , Phosphoproteins/metabolism , Sertoli Cells/drug effects , Animals , Cell Communication/physiology , Cells, Cultured , Connexin 43/biosynthesis , Connexin 43/genetics , Gap Junctions/metabolism , Male , Membrane Proteins/biosynthesis , Mice , Mice, Transgenic , Phosphoproteins/biosynthesis , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Sertoli Cells/cytology , Sertoli Cells/metabolism , Zonula Occludens-1 Protein
16.
Environ Health Perspect ; 109 Suppl 1: 21-6, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11250802

ABSTRACT

We review the significant and adverse health effects that can occur with relatively small endogenous hormonal changes in pubertal and adult humans. We discuss the effects of hormonal changes that occur within normal physiologic ranges--such as the rising levels of estrogen in peripuberty, which cause growth spurts at low levels and then the fusion of epiphyses at higher levels--and the hormonal variations during the menstrual cycle and their relation to genital phenotypic changes and intercurrent disease evolution. We turn next to adaptive changes in gonadal and other functions during aging, exercise, stress, starvation, and chronic diseases, which can serve as models for the effects of exogenous, hormonally active compounds. Then we review the states of borderline hormonal imbalances such as subclinical (having few or very mild symptoms, if any) hypothyroidism or hyperthyroidism, glucose intolerance, and other endocrine conditions. Finally, we review the deleterious systemic effects of gonadal imbalance. Information stemming from clinical observations leads to the concept of "no threshold" within the endocrine system and thus illustrates the importance of considering low-dose testing for chemicals that interfere with hormonal activity. We also urge attention to more sensitive, less visible end points such as osteoporosis, increased risk for cardiovascular disease, or cognitive changes.


Subject(s)
Endocrine System/physiology , Estrogens/pharmacology , Menstruation/physiology , Puberty/physiology , Adolescent , Adult , Aging/physiology , Endocrine System/drug effects , Endocrine System/growth & development , Estrogens/agonists , Female , Humans , Hyperthyroidism/physiopathology , Hypothyroidism/physiopathology , Male , Reference Values , Reproduction
17.
Pituitary ; 4(3): 135-43, 2001 Aug.
Article in English | MEDLINE | ID: mdl-12138986

ABSTRACT

BACKGROUND: The subcutaneous (s.c.) administration of somatostatin analogs, such as octreotide acetate (SMS) and lanreotide, in patients with thyrotropin (TSH)-secreting pituitary adenomas (TSPA's)--thyrotropinomas with residual tumor after initial surgical therapy is effective in controlling hyperthyroidism, as well as curtailing tumor growth in the majority of patients. Long-acting preparations of the above agents, i.e. SMS-LAR and lanreotide-SR, have been synthesized and can be administered as depot injections intramuscularly (i.m.) at intervals of several weeks. Recent studies have reported on preliminary data regarding the use of such preparations in patients with TSPA's. MATERIALS AND METHODS: We present two cases of TSPA's with residual tumor following transsphenoidal adenomectomy. Neither of the two patients underwent external beam pituitary irradiation. The presence and extent of tumoral TSH hypersecretion was assessed by standard biochemical and dynamic endocrine testing, while tumor size was evaluated by conventional radiographic techniques. RESULTS: In both patients, TSH secretion was effectively suppressed by SMS-LAR. Moreover, administration of this compound halted further tumor growth, as well as resulted in improved patient comfort, for 12 and 10 months respectively. CONCLUSION: Our date corroborate earlier reports on the usefulness of SMS-LAR in the medical management of patients with TSPA's who have residual disease after initial pituitary surgery and/or irradiation.


Subject(s)
Adenoma/drug therapy , Hormones/therapeutic use , Octreotide/therapeutic use , Pituitary Neoplasms/drug therapy , Thyrotropin/metabolism , Adenoma/diagnostic imaging , Adenoma/metabolism , Aged , Female , Humans , Middle Aged , Pituitary Neoplasms/diagnostic imaging , Pituitary Neoplasms/metabolism , Radionuclide Imaging , Thyrotropin/blood , Treatment Outcome
18.
Environ Health Perspect ; 107(5): 407-15, 1999 May.
Article in English | MEDLINE | ID: mdl-10210697

ABSTRACT

The U.S. Congress has passed legislation requiring the EPA to implement screening tests for identifying endocrine-disrupting chemicals. A series of workshops was sponsored by the EPA, the Chemical Manufacturers Association, and the World Wildlife Fund; one workshop focused on screens for chemicals that alter thyroid hormone function and homeostasis. Participants at this meeting identified and examined methods to detect alterations in thyroid hormone synthesis, transport, and catabolism. In addition, some methods to detect chemicals that bind to the thyroid hormone receptors acting as either agonists or antagonists were also identified. Screening methods used in mammals as well as other vertebrate classes were examined. There was a general consensus that all known chemicals which interfere with thyroid hormone function and homeostasis act by either inhibiting synthesis, altering serum transport proteins, or by increasing catabolism of thyroid hormones. There are no direct data to support the assertion that certain environmental chemicals bind and activate the thyroid hormone receptors; further research is indicated. In light of this, screening methods should reflect known mechanisms of action. Most methods examined, albeit useful for mechanistic studies, were thought to be too specific and therefore would not be applicable for broad-based screening. Determination of serum thyroid hormone concentrations following chemical exposure in rodents was thought to be a reasonable initial screen. Concurrent histologic evaluation of the thyroid would strengthen this screen. Similar methods in teleosts may be useful as screens, but would require indicators of tissue production of thyroid hormones. The use of tadpole metamorphosis as a screen may also be useful; however, this method requires validation and standardization prior to use as a broad-based screen.


Subject(s)
Antithyroid Agents/toxicity , Mass Screening , Thyroxine/antagonists & inhibitors , Triiodothyronine/antagonists & inhibitors , Animals , Behavior, Animal/drug effects , Homeostasis/drug effects , Humans , Male , Organ Size/drug effects , Sperm Count/drug effects , Testis/drug effects
19.
J Clin Endocrinol Metab ; 84(2): 476-86, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10022404

ABSTRACT

We report a large series of 25 patients with TSH-secreting tumors (23 macroadenomas) followed at the NIH. Hyperthyroid symptoms were severe in 14 patients, mild in 8, and absent in 3. Patients were divided into 2 groups according to whether their thyroid had been treated (n = 11) or not (n = 14). In untreated patients, the classical diagnostic criteria (unresponsive TRH test, high alpha-subunit, and high alpha-subunit/TSH ratio) were present, respectively, in 10, 8, and 12 cases (sensitivity, 71%, 75%, and 83%; specificity, 96%, 90%, and 65%). In treated patients, the respective sensitivities of the TRH test, alpha-subunit, and alpha-subunit/TSH ratio were 64%, 90%, and 90%, and their specificities were 100%, 82%, and 73%. Studies of thyroid hormone action revealed no evidence of acquired resistance to thyroid hormone in TSH-secreting tumors. Apparent cure was achieved in 35% of cases by surgery alone and in 22% more by combined therapies. Three deaths occurred, including 1 from metastatic thyrotroph carcinoma. Six patients had residual tumor, with symptoms of hyperthyroidism controlled with octreotide in 5. The size and invasiveness of the tumor, duration of symptoms, and intensity of hyperthyroidism were the main prognostic factors. Thus, early diagnosis and treatment are the keys to a good outcome.


Subject(s)
Adenoma/metabolism , Pituitary Neoplasms/metabolism , Thyroid Hormones/pharmacology , Thyrotropin/metabolism , Adenoma/diagnosis , Adenoma/surgery , Adolescent , Adult , Aged , Aged, 80 and over , Bromocriptine/therapeutic use , Drug Resistance , Female , Glycoprotein Hormones, alpha Subunit/blood , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Octreotide/therapeutic use , Pituitary Neoplasms/diagnosis , Pituitary Neoplasms/surgery , Radiotherapy , Thyrotropin-Releasing Hormone , Tomography, X-Ray Computed , Treatment Outcome
20.
Thyroid ; 8(9): 827-56, 1998 Sep.
Article in English | MEDLINE | ID: mdl-9777756

ABSTRACT

Synthetic chemicals are released into the environment by design (pesticides) or as a result of industrial activity. It is well known that natural environmental chemicals can cause goiter or thyroid imbalance. However, the effects of synthetic chemicals on thyroid function have received little attention, and there is much controversy over their potential clinical impact, because few studies have been conducted in humans. This article reviews the literature on possible thyroid disruption in wildlife, humans, and experimental animals and focuses on the most studied chemicals: the pesticides DDT, amitrole, and the thiocarbamate family, including ethylenethiourea, and the industrial chemicals polyhalogenated hydrocarbons, phenol derivatives, and phthalates. Wildlife observations in polluted areas clearly demonstrate a significant incidence of goiter and/or thyroid imbalance in several species. Experimental evidence in rodents, fish, and primates confirms the potentiality for thyroid disruption of several chemicals and illustrates the mechanisms involved. In adult humans, however, exposure to background levels of chemicals does not seem to have a significant negative effect on thyroid function, while exposure at higher levels, occupational or accidental, may produce mild thyroid changes. The impact of transgenerational, background exposure in utero on fetal neurodevelopment and later childhood cognitive function is now under scrutiny. There are several studies linking a lack of optimal neurological function in infants and children with high background levels of exposure to polychlorinated biphenyls (PCBs), dioxins, and/or co-contaminants, but it is unclear if the effects are caused by thyroid disruption in utero or direct neurotoxicity.


Subject(s)
Environmental Pollutants/poisoning , Thyroid Diseases/chemically induced , Thyroid Gland/physiopathology , Amitrole/poisoning , Animals , DDT/poisoning , Humans , Industrial Waste , Pesticides/poisoning , Thiocarbamates/poisoning , Thyroid Diseases/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...